首页D8Y0 • FRA
add
山德士
相关资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | 25.31亿 | 2.68% |
经营支出 | 10.24亿 | 7.11% |
净收入 | 7500.00万 | -36.17% |
净利润率 | 2.96 | -37.95% |
每股收益 | — | — |
息税折旧摊销前利润 | 2.70亿 | -21.93% |
有效税率 | 25.98% | — |
资产负债表
总资产
负债总额
| (USD) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 7.01亿 | 451.97% |
总资产 | 193.19亿 | 4.77% |
负债总额 | 109.51亿 | 9.80% |
权益总额 | 83.68亿 | — |
发行在外的股份 | 4.30亿 | — |
市净率 | 2.13 | — |
资产回报率 | 2.15% | — |
资本回报率 | 3.24% | — |
现金流
现金净变动
| (USD) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | 7500.00万 | -36.17% |
来自运营的现金 | 1.14亿 | 169.41% |
投资现金 | -1.97亿 | -110.70% |
融资现金 | -1.14亿 | -240.74% |
现金净变动 | -2.04亿 | -869.81% |
自由现金流 | 1.03亿 | -35.27% |
简介
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland. Sandoz is one of the leading global generics businesses. Wikipedia
CEO
成立时间
1886
员工数量
22,633
